Who should not take Ozempic, Zepbound or another GLP-1?
The short answer
Who should not take Ozempic? It and the seven other GLP-1 medicines we track must not be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, or by people who've had a serious hypersensitivity (allergic) reaction to the drug. Several are also not recommended in severe gastroparesis.
Key takeaways
- All eight GLP-1 medicines must not be used with a personal or family history of medullary thyroid carcinoma or with MEN 2.
- All eight must not be used after a serious allergic reaction to the drug or its ingredients.
- Tell your prescriber about any thyroid cancer in your family so they can establish the type.
- Most labels say these medicines are not recommended in severe gastroparesis, and four say not to combine them with another GLP-1.
- Tell your prescriber about past pancreatitis, gallbladder problems, kidney disease, diabetic eye disease, or planned surgery.
A label can say “do not use” in more than one way. A contraindication is the strongest: the medicine should not be used in that situation. A limitation of use or a “not recommended” statement is a step below. Then there are groups in whom the medicine hasn’t been studied enough to say. This page sorts what the eight GLP-1 labels say into those categories.
It lists what the labels state. It can’t tell you whether you personally should take one of these medicines. Your prescriber makes that decision with your full history.
The two contraindications on every label
All eight labels in our records (Zepbound, Mounjaro, Foundayo, Trulicity, Wegovy, Ozempic, Rybelsus and Saxenda) list the same two contraindications.
1. Medullary thyroid carcinoma or MEN 2
Each label is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Three parts of that sentence are worth reading closely:
- Personal or family. A relative’s history counts, not only your own.
- Medullary. The contraindication names one specific type of thyroid cancer. The labels don’t list other thyroid cancers or other thyroid conditions as contraindications.
- MEN 2. Multiple Endocrine Neoplasia syndrome type 2, a rare inherited condition that causes tumors in hormone glands, is named on every label. If you’ve been told you have it, tell your prescriber.
This contraindication comes from the boxed warning about thyroid C-cell tumors. A boxed warning is the strongest kind the FDA requires. It’s on every one of these labels and is explained in the GLP-1 safety guide.
2. Serious hypersensitivity
Each label is contraindicated in people with a serious hypersensitivity (allergic) reaction to the active ingredient or to any of the product’s other ingredients:
- tirzepatide, for Zepbound and Mounjaro
- semaglutide, for Wegovy, Ozempic and Rybelsus
- orforglipron, for Foundayo
- dulaglutide, for Trulicity
- liraglutide, for Saxenda
The Wegovy, Ozempic, Rybelsus and Saxenda labels note that serious hypersensitivity reactions, including anaphylaxis, a sudden and severe whole-body reaction, and angioedema, swelling under the skin, have been reported. Brands can share an active ingredient. So a serious reaction to one semaglutide product is a contraindication to the others, and the same holds for the two tirzepatide products.
Who is a GLP-1 “not recommended” for?
People with severe gastroparesis
Gastroparesis is delayed emptying of the stomach, and GLP-1 medicines slow stomach emptying further. The Zepbound, Mounjaro, Foundayo and Trulicity labels each state that the medicine is not recommended in patients with severe gastroparesis. Our side-effect records show the same statement in the warnings for Wegovy, Ozempic, Rybelsus and Saxenda.
People with severe liver impairment (Foundayo)
Foundayo is not recommended for use in patients with severe hepatic (liver) impairment (Child-Pugh Class C, the most severe grade on that liver scale). No other label in our records has a “not recommended” statement for liver impairment. The Trulicity label says clinical experience in patients with mild, moderate or severe hepatic impairment is limited, and to use it with caution in those patients.
People already taking another GLP-1
Four labels in our records carry this limitation:
- Zepbound: taking it with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.
- Wegovy: use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
- Saxenda: taking it with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended.
- Foundayo: use with another GLP-1 receptor agonist is not recommended.
The practical point stands across the class: one of these medicines at a time, and a switch is planned by your prescriber. See the switching planner.
Pregnancy and breastfeeding
The labels for the weight-management products say the medicine is discontinued when a pregnancy is recognized. For Zepbound, Foundayo and Saxenda that instruction has no conditions. For Wegovy it applies to patients using it for weight reduction. The reason given is that weight loss offers no benefit to a pregnant patient and may cause fetal harm.
Foundayo is not recommended for nursing women, and the semaglutide tablet labels advise against breastfeeding during treatment. The semaglutide labels also say to stop at least 2 months before a planned pregnancy. All of this is set out on the pregnancy and breastfeeding page.
Children and teenagers
Here’s what the labels in our records say about pediatric use:
- Zepbound: safety and effectiveness have not been established in pediatric patients.
- Foundayo: safety and effectiveness have not been established in pediatric patients.
- Mounjaro: not established in pediatric patients less than 10 years of age.
- Trulicity: not established in pediatric patients less than 10 years of age.
- Saxenda: safety and effectiveness in pediatric patients with type 2 diabetes have not been established.
The Mounjaro label also says the Mounjaro KwikPen is not recommended for self-administration by pediatric patients.
Not every product excludes younger patients. In our drug records, Wegovy injection and Saxenda are approved for weight reduction in pediatric patients aged 12 years and older with obesity (for Saxenda, with body weight above 60 kg), and Mounjaro and Trulicity are approved for type 2 diabetes from 10 years of age.
A stopping rule that is on the label: Saxenda
One label tells prescribers when to stop for lack of effect. For Saxenda, the label says to evaluate the change in body weight 16 weeks after starting, and to discontinue Saxenda if the adult patient hasn’t lost at least 4% of baseline body weight (their weight at the start). The reason given is that the patient is unlikely to achieve and sustain clinically meaningful weight loss with continued treatment.
Conditions that call for caution, not exclusion
The warnings sections of the labels describe risks that don’t bar anyone from treatment but that your prescriber will want to know about. From our side-effect records, these include acute pancreatitis, gallbladder disease, acute kidney injury linked to dehydration, diabetic retinopathy complications (eye damage from diabetes) in people with type 2 diabetes, low blood sugar when the medicine is combined with insulin or a sulfonylurea, and the risk of pulmonary aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation.
The labels in our records don’t make a history of these conditions a contraindication. They’re reasons to tell your prescriber about:
- any past pancreatitis or gallbladder problems
- kidney disease
- diabetic eye disease
- insulin or sulfonylurea use (see drug interactions)
- any planned surgery or procedure involving anesthesia or sedation
How often the common reactions occurred in trials is on the side effects guide.
Frequently asked questions
Who should not take Ozempic?
The Ozempic label lists two contraindications, situations where it must not be used: a personal or family history of medullary thyroid carcinoma or MEN 2, and a serious hypersensitivity (allergic) reaction to semaglutide or any other ingredient in Ozempic. The label's warnings also say Ozempic is not recommended in patients with severe gastroparesis. Your prescriber assesses everything else.
Can you take Zepbound if thyroid cancer runs in your family?
It depends on the type. Zepbound must not be used by patients with a personal or family history of medullary thyroid carcinoma, a specific kind of thyroid cancer, or with MEN 2. The label doesn't list other thyroid conditions as contraindications. Tell your prescriber about any thyroid cancer in your family so they can establish the type.
Can you take a GLP-1 if you have gastroparesis?
The labels say these medicines are not recommended in patients with severe gastroparesis, a stomach that empties very slowly. That statement is on the Zepbound, Mounjaro, Foundayo and Trulicity labels and in the warnings recorded for Wegovy, Ozempic, Rybelsus and Saxenda. The wording is about severe gastroparesis, and what counts as severe is a clinical judgment for your prescriber.
Can teenagers take Zepbound or Wegovy?
The Zepbound label says safety and effectiveness have not been established in pediatric patients, and the Foundayo label says the same. Our records include a Wegovy injection trial in pediatric patients aged 12 and older with obesity, and Mounjaro and Trulicity are not established under 10 years of age. A pediatric prescription is a specialist decision.
Can I take Zepbound and Ozempic together?
The Zepbound label says taking it with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. Ozempic is a GLP-1 receptor agonist, so the two are not taken together under that label. The Wegovy, Saxenda and Foundayo labels contain equivalent limits.
Sources (40)
- 1.FDA label (DailyMed): Zepbound prescribing information, section 4
“ZEPBOUND is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].”
- 2.FDA label (DailyMed): Zepbound prescribing information, section 4
“ZEPBOUND is contraindicated in patients with: Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND.”
- 3.FDA label (DailyMed): Zepbound prescribing information, section 1
“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 4.FDA label (DailyMed): Zepbound prescribing information, section 5.2
“ZEPBOUND is not recommended in patients with severe gastroparesis.”
- 5.FDA label (DailyMed): Zepbound prescribing information, section 8.4
“The safety and effectiveness of ZEPBOUND have not been established in pediatric patients.”
- 6.FDA label (DailyMed): Zepbound prescribing information, section 8.1
“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized (see Clinical Considerations).”
- 7.FDA label (DailyMed): Mounjaro prescribing information, section 4
“MOUNJARO is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
- 8.FDA label (DailyMed): Mounjaro prescribing information, section 4
“MOUNJARO is contraindicated in patients with: Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO.”
- 9.FDA label (DailyMed): Mounjaro prescribing information, section 5.6
“MOUNJARO is not recommended in patients with severe gastroparesis.”
- 10.FDA label (DailyMed): Mounjaro prescribing information, section 8.4
“The safety and effectiveness of MOUNJARO have not been established in pediatric patients less than 10 years of age.”
- 11.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“MOUNJARO KwikPen is not recommended for self-administration by pediatric patients. MOUNJARO KwikPen is not recommended for self-administration by those who are visually impaired.”
- 12.FDA label (DailyMed): Foundayo prescribing information, section 4
“FOUNDAYO is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].”
- 13.FDA label (DailyMed): Foundayo prescribing information, section 4
“FOUNDAYO is contraindicated in patients with: Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO.”
- 14.FDA label (DailyMed): Foundayo prescribing information, section 1
“Concomitant use with another GLP-1 receptor agonist is not recommended.”
- 15.FDA label (DailyMed): Foundayo prescribing information, section 5.3
“FOUNDAYO is not recommended in patients with severe gastroparesis.”
- 16.FDA label (DailyMed): Foundayo prescribing information, section 8.6
“FOUNDAYO is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C) [see Clinical Pharmacology (12.3)].”
- 17.FDA label (DailyMed): Foundayo prescribing information, section 8.4
“Safety and effectiveness of FOUNDAYO have not been established in pediatric patients.”
- 18.FDA label (DailyMed): Foundayo prescribing information, section 8.2
“FOUNDAYO is not recommended for nursing women.”
- 19.FDA label (DailyMed): Foundayo prescribing information, section 8.1
“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus and discontinue FOUNDAYO.”
- 20.FDA label (DailyMed): Trulicity prescribing information, section 4
“TRULICITY is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].”
- 21.FDA label (DailyMed): Trulicity prescribing information, section 4
“TRULICITY is contraindicated in patients with: Serious hypersensitivity reaction to dulaglutide or to any of the product components.”
- 22.FDA label (DailyMed): Trulicity prescribing information, section 5.6
“TRULICITY is not recommended in patients with severe gastroparesis.”
- 23.FDA label (DailyMed): Trulicity prescribing information, section 8.4
“The safety and effectiveness of TRULICITY have not been established in pediatric patients less than 10 years of age.”
- 24.FDA label (DailyMed): Trulicity prescribing information, section 8.7
“However, there is limited clinical experience in patients with mild, moderate, or severe hepatic impairment; therefore, use TRULICITY with caution in these patient populations.”
- 25.FDA label (DailyMed): Wegovy prescribing information, section 4
“a personal or family history of MTC or in patients with MEN 2”
- 26.FDA label (DailyMed): Wegovy prescribing information, section 4
“a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in WEGOVY injection or WEGOVY tablet. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with WEGOVY”
- 27.FDA label (DailyMed): Wegovy prescribing information, section 1
“Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
- 28.FDA label (DailyMed): Wegovy prescribing information, section 8.1
“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus. Discontinue WEGOVY in pregnant patients who are using it for weight reduction”
- 29.FDA label (DailyMed): Ozempic prescribing information, section 4
“A personal or family history of MTC or in patients with MEN 2”
- 30.FDA label (DailyMed): Ozempic prescribing information, section 4
“A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC”
- 31.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 4
“A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
- 32.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 4
“A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with semaglutide tablets”
- 33.FDA label (DailyMed): Saxenda prescribing information, section 4
“Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
- 34.FDA label (DailyMed): Saxenda prescribing information, section 4
“Patients with a serious hypersensitivity reaction to liraglutide or to any of the excipients in SAXENDA. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with SAXENDA”
- 35.FDA label (DailyMed): Saxenda prescribing information, section 1
“SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 36.FDA label (DailyMed): Saxenda prescribing information, section 1
“The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established.”
- 37.FDA label (DailyMed): Saxenda prescribing information, section 8.1
“Additionally, weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus, and discontinue SAXENDA”
- 38.FDA label (DailyMed): Saxenda prescribing information, section 2.2
“Evaluate the change in body weight 16 weeks after initiating SAXENDA and discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.”
- 39.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“ZEPBOUND KwikPen is not recommended for self-administration by those who are visually impaired.”
- 40.FDA label (DailyMed): Wegovy prescribing information, section 14.3, Table 18
“After 68 weeks, treatment with WEGOVY injection resulted in a statistically significant reduction in percent BMI compared with placebo.”
